Who Paid My Doc
Benjamin Feibel
Adult Reconstructive Orthopaedic Surgery Shreveport, LA Medical Doctor
NPI 1114380656 CMS profile 8810629
1455 E Bert Kouns Industrial Loop Ste 210, Shreveport, LA 71105
General payments
$11,788
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Benjamin Feibel of Shreveport, LA is reported in the CMS Open Payments database as having received $11,788 across 182 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 52nd percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,754 | 51 | |
| 2024 | General | $1,940 | 29 | |
| 2023 | General | $3,684 | 50 | |
| 2022 | General | $1,104 | 20 | |
| 2021 | General | $2,307 | 32 |
Beside peers
- Benjamin Feibel
- Adult Reconstructive Orthopaedic Surgery median
- Middle half of Adult Reconstructive Orthopaedic Surgery
- National median
In program year 2025, general payments to Benjamin Feibel were reported at $2,754. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.
Show as a table
| Year | Benjamin Feibel | Adult Reconstructive Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $1,416 | $292–$9,336 | $163 |
| 2020 | $0 | $647 | $141–$6,474 | $114 |
| 2021 | $2,307 | $1,073 | $211–$6,497 | $132 |
| 2022 | $1,104 | $1,217 | $236–$6,299 | $149 |
| 2023 | $3,684 | $1,082 | $246–$6,818 | $160 |
| 2024 | $1,940 | $1,575 | $323–$8,944 | $164 |
| 2025 | $2,754 | $1,406 | $318–$8,709 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
1,040
Drug cost
$6,247
Branded share of claims
28.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 237 | $1,788 | |
| Celecoxib | Generic | 139 | $1,164 | |
| Ondansetron Hcl | Generic | 112 | $556 | |
| Doxycycline Hyclate | Generic | 20 | $524 | |
| Ondansetron Odt Ondansetron | Brand | 44 | $517 | |
| Tramadol Hcl | Generic | 175 | $412 | |
| Cyclobenzaprine Hcl | Generic | 15 | $227 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 17 | $220 | |
| Methylprednisolone | Generic | 35 | $214 | |
| Ciprofloxacin Hcl | Generic | 14 | $181 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 92 billing codesPaid by Medicare
$229,425
Medicare patients
452
Services billed
5,046
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 32% | |
| Diabetes | 29% | |
| Depression | 26% | |
| Chronic kidney disease | 23% | |
| Atrial fibrillation | 21% | |
| Osteoporosis | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 | Office | 12 | 816 | $5,728 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 144 | 1,966 | $1,454 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
182 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Reconstructive Orthopaedic Surgery in Louisiana
Eric Greber
Adult Reconstructive Orthopaedic Surgery · Thibodaux, LA
Wesley Clark
Adult Reconstructive Orthopaedic Surgery · New Orleans, LA
Paul Buzhardt
Adult Reconstructive Orthopaedic Surgery · Lafayette, LA
Fernando Nussenbaum
Adult Reconstructive Orthopaedic Surgery · Mandeville, LA
Alex Betech
Adult Reconstructive Orthopaedic Surgery · Baton Rouge, LA
Robert Duarte
Adult Reconstructive Orthopaedic Surgery · Lake Charles, LA
Related records
Adult Reconstructive Orthopaedic Surgery in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Adult Reconstructive Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.